The role of human serum albumin (HSA) in the delivery of anticancer metallodrugs remains unclear and requires further investigation. To this end, bioconjugates of HSA with the metallodrugs cisplatin (CIS), oxaliplatin (OXA) and auranofin (AF) were prepared, characterised by ESI-MS and ICP, and tested for their cytotoxic properties in A2780 and HCT116 cancer cells. Significant differences in the biological activities of the two Pt bioconjugates compared to that of the Au bioconjugate emerged, and they are interpreted and discussed in the context of the available literature.
The impact of albumin conjugation on the cytotoxic properties of cisplatin, oxaliplatin and auranofin in cancer cells
Lorenzo ChiaveriniCo-primo
Investigation
;Maria Letizia TrincavelliWriting – Review & Editing
;Tiziano Marzo
Penultimo
Supervision
;Chiara GiacomelliUltimo
Investigation
2026-01-01
Abstract
The role of human serum albumin (HSA) in the delivery of anticancer metallodrugs remains unclear and requires further investigation. To this end, bioconjugates of HSA with the metallodrugs cisplatin (CIS), oxaliplatin (OXA) and auranofin (AF) were prepared, characterised by ESI-MS and ICP, and tested for their cytotoxic properties in A2780 and HCT116 cancer cells. Significant differences in the biological activities of the two Pt bioconjugates compared to that of the Au bioconjugate emerged, and they are interpreted and discussed in the context of the available literature.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
